Targeting a specific cancer marker in pancreatic cancer
Targeting Disease Specific Tn Antigen in Pancreatic Cancer
This study is looking at a tough type of pancreatic cancer to find new treatments that can better target certain markers on cancer cells, with the hope of improving outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11327964 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. It aims to develop new therapies that target specific carbohydrate antigens (Tn and Sialyl Tn) found on the surface of cancer cells, which are linked to poor patient outcomes. The study will investigate how these antigens influence cancer growth and spread, and how a novel monoclonal antibody can effectively target and destroy these cancer cells. By understanding the role of these antigens, the research seeks to improve treatment responses for patients with advanced PDAC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced or metastatic disease.
Not a fit: Patients with early-stage pancreatic cancer or those whose tumors do not express Tn or Sialyl Tn antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar cancer-associated antigens, indicating potential for success with this novel approach.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Radhakrishnan, Prakash — University of Louisville
- Study coordinator: Radhakrishnan, Prakash
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.